Stephen J. Freedland, MD, discusses the correlation between treatment suspension and HRQoL in patients with nmHSPC who were enrolled on the phase 3 EMBARK trial.
Multiple surveys of patient-reported outcomes from the phase 3 EMBARK trial revealed no meaningful differences in pain progression or urinary symptoms and bowel symptoms or function over 205 weeks of follow-up. Enzalutamide does not worsen health-related quality of life compared with androgen deprivation therapy in patients with high-risk biochemically recurrence nmCSPC.
Treatment intensification with the androgen receptor inhibitor enzalutamide shows benefit in patients with biochemically recurrent prostate cancer. Data show enzalutamide treatments are safe and effective compared with ADT alone in patients with high-risk biochemically recurrent prostate cancer.
WEDNESDAY, Oct. 18, 2023 (HealthDay News) For patients with prostate cancer with high-risk biochemical recurrence, enzalutamide plus leuprolide is best for metastasis-free survival, according to a study published in